These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17332346)

  • 61. Molecular target therapies in endometrial cancer: from the basic research to the clinic.
    Gadducci A; Tana R; Cosio S; Fanucchi A; Genazzani AR
    Gynecol Endocrinol; 2008 May; 24(5):239-49. PubMed ID: 18569027
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of mTOR in head and neck cancer cells alters endothelial cell morphology in a paracrine fashion.
    Duarte A; André-Grégoire G; Trillet K; Thys A; Bidère N; Ribeiro-Silva A; Gavard J
    Mol Carcinog; 2019 Jan; 58(1):161-168. PubMed ID: 30230038
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
    Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
    Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling.
    Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z
    Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer.
    Nathan CO; Franklin S; Abreo FW; Nassar R; De Benedetti A; Glass J
    J Clin Oncol; 1999 Sep; 17(9):2909-14. PubMed ID: 10561370
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients.
    John K; Rösner I; Keilholz U; Gauler T; Bantel H; Grünwald V
    Eur J Cancer; 2015 Aug; 51(12):1596-602. PubMed ID: 26048456
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mammalian target of rapamycin.
    Meric-Bernstam F; Mills GB
    Semin Oncol; 2004 Dec; 31(6 Suppl 16):10-7; discussion 33. PubMed ID: 15799239
    [TBL] [Abstract][Full Text] [Related]  

  • 69. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.
    Kwon CH; Zhu X; Zhang J; Baker SJ
    Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
    Hildebrandt MA; Lippman SM; Etzel CJ; Kim E; Lee JJ; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
    Clin Cancer Res; 2012 Jul; 18(13):3705-13. PubMed ID: 22577058
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
    Fong P; Meng LR
    Med Sci Monit Basic Res; 2014 Sep; 20():146-52. PubMed ID: 25266877
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The applicability of mTOR inhibition in solid tumors.
    Konings IR; Verweij J; Wiemer EA; Sleijfer S
    Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
    Pitter KL; Galbán CJ; Galbán S; Tehrani OS; Li F; Charles N; Bradbury MS; Becher OJ; Chenevert TL; Rehemtulla A; Ross BD; Holland EC; Hambardzumyan D
    PLoS One; 2011 Jan; 6(1):e14545. PubMed ID: 21267448
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
    Marshall G; Howard Z; Dry J; Fenton S; Heathcote D; Gray N; Keen H; Logie A; Holt S; Smith P; Guichard SM
    Biochem Soc Trans; 2011 Apr; 39(2):456-9. PubMed ID: 21428919
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibitors of the mammalian target of rapamycin.
    Dancey JE
    Expert Opin Investig Drugs; 2005 Mar; 14(3):313-28. PubMed ID: 15833062
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.
    Zhang W; Zhu J; Efferson CL; Ware C; Tammam J; Angagaw M; Laskey J; Bettano KA; Kasibhatla S; Reilly JF; Sur C; Majumder PK
    Cancer Res; 2009 Sep; 69(18):7466-72. PubMed ID: 19738074
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.
    Bresin A; Cristofoletti C; Caprini E; Cantonetti M; Monopoli A; Russo G; Narducci MG
    J Invest Dermatol; 2020 May; 140(5):1045-1053.e6. PubMed ID: 31682844
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical development of mammalian target of rapamycin inhibitors.
    Dancey JE
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1101-14. PubMed ID: 12512385
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effect of single agent oral fusaric acid (FA) on the growth of subcutaneously xenografted SCC-1 cells in a nude mouse model.
    Ruda JM; Beus KS; Hollenbeak CS; Wilson RP; Stack BC
    Invest New Drugs; 2006 Sep; 24(5):377-81. PubMed ID: 16505952
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
    Rao RD; Buckner JC; Sarkaria JN
    Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.